Company Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors.
In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease.
Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas.
It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV.
Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
| Country | United Kingdom |
| Founded | 2009 |
| IPO Date | May 23, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 284 |
| CEO | Kevin Lee |
Contact Details
Address: Portway Building, Blocks A & B Cambridge, CB21 6GS United Kingdom | |
| Phone | 44 1223 261 503 |
| Website | bicycletherapeutics.com |
Stock Details
| Ticker Symbol | BCYC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001761612 |
| CUSIP Number | 088786108 |
| ISIN Number | US0887861088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kevin Lee M.B.A., Ph.D. | Chief Executive Officer and Executive Director |
| Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE | Co-Founder and Non-Executive Director |
| Alethia Rene Young | Chief Financial Officer |
| Dr. Santiago Arroyo M.D., Ph.D. | Chief Development Officer |
| Dr. Christian Heinis | Scientific Founder |
| Alistair Milnes | Chief Operating Officer |
| Travis Thompson | Senior Vice President, Chief Accounting Officer and Principal Accounting Officer |
| Dr. Michael Skynner B.sc. Ph.d., Ph.D. | Chief Technology Officer |
| Stephanie Yao | Senior Vice President of Investor Relations and Corporate Communications |
| Zafar Qadir | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 144 | Filing |
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 23, 2024 | 8-K | Current Report |
| Oct 3, 2024 | 144 | Filing |
| Oct 3, 2024 | 144 | Filing |
| Oct 3, 2024 | 144 | Filing |